Radar Telegram alerts Open Radar

The US Food and Drug Administration (FDA) has approved Switzerland-based Roche's Vilsardelli for the treatment of advanced breast cancer in combination with Novartis' Afinitor, the Wall Street Journal reports. Roche expects annual sales of the new drug to exceed 3 billion Swiss francs ($3.57 billion) at its peak, potentially making it the company's best-selling product.

תרגם לעברית

Кролик с Неглинной · · Source

🇺🇸 USA · וול סטריט · Map

The US Food and Drug Administration (FDA) has approved Switzerland-based Roche's Vilsardelli for the treatment of advanced breast cancer in combination with Novartis' Afinitor, the Wall Street Journal reports. Roche expects annual sales of the new drug to exceed 3 billion Swiss francs ($3.57 billion) at its peak, potentially making it the company's best-selling product.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram